Tectonic Therapeutics TECX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Tectonic Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tectonic Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tectonic Therapeutics's cash & equivalents?
- Tectonic Therapeutics (TECX) reported cash & equivalents of $236.89M in Q1 2026.
- How has Tectonic Therapeutics's cash & equivalents changed year-over-year?
- Tectonic Therapeutics's cash & equivalents decreased by 22.8% year-over-year, from $306.83M to $236.89M.
- What is the long-term trend for Tectonic Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Tectonic Therapeutics's cash & equivalents has grown at a -0.5% compound annual growth rate (CAGR), from $259.68M to $253.8M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.